NewsBenzingaBioCryst Pharma erhöht die Umsatzprognose für das Geschäftsjahr 2026 von 690,000 Mio. $–715,000 Mio. $ auf 715,000 Mio. $–730,000 Mio. $ gegenüber der Schätzung von 710,134 Mio. $ BioCryst Pharma erhöht die Umsatzprognose für das Geschäftsjahr 2026 von 690,000 Mio. $–715,000 Mio. $ auf 715,000 Mio. $–730,000 Mio. $ gegenüber der Schätzung von 710,134 Mio. $ Benzinga 2026.11.04 12:06 (GMT+0) Open on Benzinga Other news Rantizo (Nasdaq: RNTZ) Issues Letter to Shareholders Outlining Revenue-Focused American Drone Strategy After $258.8 Million Acquisition Dear Nvidia Stock Fans, Mark Your Calendars for December 10 Nvidia clarifies when it will — and won’t —keep financing neoclouds Global-E Online Stock Is Falling Wednesday: What's Going On? Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6
Rantizo (Nasdaq: RNTZ) Issues Letter to Shareholders Outlining Revenue-Focused American Drone Strategy After $258.8 Million Acquisition
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease